Legend Biotech (LEGN) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Legend Biotech’s revenues soared in the third quarter of 2024, driven by the impressive sales growth of their cell therapy, CARVYKTI®, which achieved a remarkable 87.6% year-over-year increase. The company expanded its commercial production capabilities in Belgium and launched new operations in Switzerland, bolstering its global reach. With a strong cash position of $1.2 billion, Legend Biotech continues to solidify its leadership in cell therapy innovation.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
